[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2014C068I2 - - Google Patents

Info

Publication number
BE2014C068I2
BE2014C068I2 BE2014C068C BE2014C068C BE2014C068I2 BE 2014C068 I2 BE2014C068 I2 BE 2014C068I2 BE 2014C068 C BE2014C068 C BE 2014C068C BE 2014C068 C BE2014C068 C BE 2014C068C BE 2014C068 I2 BE2014C068 I2 BE 2014C068I2
Authority
BE
Belgium
Prior art keywords
present
immunoglobulin
humanized
human
humanized immunoglobulin
Prior art date
Application number
BE2014C068C
Other languages
English (en)
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24814673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C068(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BE2014C068I2 publication Critical patent/BE2014C068I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2014C068C 1996-08-15 2014-11-12 BE2014C068I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/700,737 US7147851B1 (en) 1996-08-15 1996-08-15 Humanized immunoglobulin reactive with α4β7 integrin

Publications (1)

Publication Number Publication Date
BE2014C068I2 true BE2014C068I2 (fr) 2017-09-22

Family

ID=24814673

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C068C BE2014C068I2 (fr) 1996-08-15 2014-11-12

Country Status (19)

Country Link
US (3) US7147851B1 (fr)
EP (2) EP0918797B2 (fr)
JP (3) JP4171071B2 (fr)
CN (1) CN100406562C (fr)
AT (1) ATE321788T1 (fr)
AU (1) AU730326C (fr)
BE (1) BE2014C068I2 (fr)
BR (1) BRPI9711079B1 (fr)
CA (1) CA2263106C (fr)
DE (1) DE69735596T3 (fr)
DK (1) DK0918797T4 (fr)
ES (1) ES2262186T5 (fr)
IL (3) IL128052A0 (fr)
LT (1) LTC0918797I2 (fr)
LU (1) LU92596I2 (fr)
NZ (1) NZ334226A (fr)
PT (1) PT918797E (fr)
SI (1) SI0918797T2 (fr)
WO (1) WO1998006248A2 (fr)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU2011226857B2 (en) * 1998-05-13 2013-09-19 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
EP1133315B1 (fr) * 1998-11-25 2006-02-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Antagonistes de l'integrine alpha e beta 7 utilises comme agents therapeutiques pour traiter les maladies inflammatoires
EE05662B1 (et) * 1999-04-22 2013-06-17 Biogen, Inc. Fibroosi ravimise kompositsioon, mis kasutab integriin alfa-4 subhiku antagonisti ja selle kompositsiooni kasutamine
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
AU2006220426B2 (en) * 2000-04-14 2008-10-30 Genentech Inc. Method of administering an antibody
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
DE60235408D1 (de) * 2001-12-17 2010-04-01 Univ Cardiff Enzymatische spaltbare reagenzien zum spezifischen targeting von krankheitsherden
WO2003066662A2 (fr) 2002-02-05 2003-08-14 Genentech, Inc. Purification de proteines
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7323553B2 (en) 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
AU2003231293A1 (en) 2002-05-02 2003-11-17 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
EP2368578A1 (fr) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
CN1745175A (zh) * 2003-02-01 2006-03-08 神经实验室有限公司 自动免疫产生针对可溶性A－β的抗体
EP3095793B1 (fr) 2003-07-28 2020-03-25 Genentech, Inc. Réduction de protéine a pendant une chromatographie d'affinité sur protéine a
CA2536918A1 (fr) 2003-08-26 2005-03-03 Leland Shapiro Compositions et procedes pour molecules de fusion fc de l'alpha-1 antitrypsine
JP2007521248A (ja) 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
DK2177537T3 (da) 2004-01-09 2011-12-12 Pfizer Antistoffer til MAdCAM
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
PL3530673T3 (pl) * 2004-09-03 2022-08-01 Genentech, Inc. Humanizowani antagoniści anty-beta7 i ich zastosowania
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2007007151A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Utilisation d'anticorps anti mad-cam dans le traitement de l'emphyseme
WO2007007160A2 (fr) * 2005-07-11 2007-01-18 Pfizer Limited Anticorps anti-madcam servant a traiter la fievre
WO2007061679A1 (fr) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. IMMUNOGLOBULINE HUMANISEE REACTIVE AVEC L’INTEGRINE α4β7
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (fr) 2006-12-21 2008-07-03 Millipore Corporation Purification de protéines
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US7947813B2 (en) 2007-01-22 2011-05-24 Genentech, Inc. Polyelectrolyte precipitation and purification of proteins
AU2008223541B2 (en) * 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
EP2125892A2 (fr) * 2007-03-20 2009-12-02 Millennium Pharmaceuticals, Inc. Acides nucléiques codant une immunoglobuline humanisée qui se lie à l'intégrine a4b7
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CN106366192B (zh) 2007-06-25 2020-03-27 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
PT3597659T (pt) 2007-07-09 2023-04-04 Genentech Inc Prevenção da redução de ligações de dissulfureto durante a produção recombinante de polipéptidos
EP2182983B1 (fr) * 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Traitement de maladies amyloïdogéniques avec anti-abeta anticorps humanise
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20090148435A1 (en) 2007-10-30 2009-06-11 Genentech, Inc. Antibody purification by cation exchange chromatography
RU2503720C2 (ru) * 2008-01-11 2014-01-10 Астеллас Фарма Инк. УЛУЧШЕННОЕ ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ α9-ИНТЕГРИНУ
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8999702B2 (en) 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
EP2321337B2 (fr) 2008-08-14 2018-10-10 Genentech, Inc. Procédés d'élimination d'un contaminant au moyen de la chromatographie à membrane échangeuse d'ions à déplacement de protéines
EP2334323A2 (fr) 2008-09-10 2011-06-22 F. Hoffmann-La Roche AG Compositions et procédés permettant d éviter la dégradation oxydative des protéines
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
ES2749232T3 (es) 2008-12-16 2020-03-19 Emd Millipore Corp Reactor de tanque agitado y procedimiento
EP2358734A1 (fr) 2008-12-16 2011-08-24 Millipore Corporation Purification de protéines
ES2547712T3 (es) 2009-02-27 2015-10-08 Genentech, Inc. Métodos y composiciones para el marcado de proteínas
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
AU2016208453B2 (en) * 2009-03-20 2018-02-22 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
AU2013205341B2 (en) * 2009-03-20 2016-05-05 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
CN102459628A (zh) 2009-05-13 2012-05-16 基酶有限公司 抗人cd52 免疫球蛋白
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
CA2772653C (fr) 2009-09-01 2019-06-25 Genentech, Inc. Purification amelioree d'une proteine grace a une elution modifiee de la proteine a
PL2493922T3 (pl) 2009-10-26 2017-07-31 F.Hoffmann-La Roche Ag Sposób wytwarzania glikozylowanych immunoglobulin
CN106983862A (zh) 2010-03-22 2017-07-28 弗·哈夫曼-拉罗切有限公司 对于稳定含有蛋白质的制剂有用的组合物和方法
CA2794864A1 (fr) 2010-05-03 2011-11-10 Genentech, Inc. Compositions et procedes utiles pour la reduction de la viscosite de formulations contenant des proteines
EP2571903B1 (fr) 2010-05-17 2019-09-04 EMD Millipore Corporation Polymères répondant à des stimuli pour la purification de biomolécules
ES2599412T3 (es) 2010-05-28 2017-02-01 F. Hoffmann-La Roche Ag Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
CA2802756C (fr) 2010-06-24 2021-05-04 Genentech, Inc. Compositions et methodes pour stabiliser des preparations contenant des proteines
KR20130100125A (ko) 2010-08-13 2013-09-09 제넨테크, 인크. 질환의 치료를 위한, ＩＬ-1β 및 ＩＬ-18에 대한 항체
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR102308938B1 (ko) 2011-05-02 2021-10-01 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
EP3628327A1 (fr) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, procédés et utilisations de molécules de fusion de l'alpha-1 antitrypsine
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
SG11201403437TA (en) 2011-12-22 2014-07-30 Genentech Inc Ion exchange membrane chromatography
KR20140137347A (ko) * 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
EA201992881A3 (ru) * 2012-01-12 2020-12-30 Милленниум Фармасьютикалз, Инк. Композиция анти-47 антитела
JP6225162B2 (ja) 2012-03-27 2017-11-01 ジェネンテック， インコーポレイテッド 組換えタンパク質の改良された収集操作
CN103374073A (zh) * 2012-04-26 2013-10-30 中国科学院上海生命科学研究院 识别活化形式整合素α4β7的人源化单克隆抗体
HRP20250525T1 (hr) 2012-05-18 2025-06-20 Genentech, Inc. Visokokoncentrirane formulacije monoklonskog protutijela
CN104994885B (zh) 2012-12-19 2017-09-29 基因泰克公司 用于放射性卤素蛋白质标记的方法和组合物
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2015287760B2 (en) 2014-07-09 2019-06-20 Genentech, Inc. pH adjustment to improve thaw recovery of cell banks
KR20240033093A (ko) 2014-10-06 2024-03-12 케모센트릭스, 인크. C-c 케모카인 수용체 타입 9 (ccr9)의 억제제 및 항-알파4베타7 인테그린 차단 항체의 조합 요법
JP2017537105A (ja) 2014-11-26 2017-12-14 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 瘻孔を伴うクローン病の治療用ベドリズマブ
US20170360926A1 (en) 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
MX2018001668A (es) 2015-08-11 2018-05-07 Univ Osaka Anticuerpo.
KR20180039726A (ko) * 2015-09-04 2018-04-18 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 인슐린 면역글로불린 융합 단백질
EP3397274A1 (fr) 2015-12-31 2018-11-07 The Regents of the University of Colorado, a body corporate Méthodes et utilisations de l'alpha-1 anti-trypsine, ou de ses formes recombinées, sur une maladie du greffon contre l'hôte, réfractaire aux stéroïdes, impliquant des complications gastro-intestinales
WO2017160699A2 (fr) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Méthode de traitement de la réaction du greffon contre l'hôte (gvd)
CN109153721A (zh) * 2016-03-14 2019-01-04 千禧制药公司 治疗或预防移植物抗宿主疾病的方法
WO2017165742A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
CA3019373A1 (fr) 2016-03-29 2017-10-05 Geltor, Inc. Expression de proteines dans des bacteries gram negatif, avec un rapport du volume periplasmique au volume cytoplasmique compris entre 0,5:1 et 10:1
MA44864A (fr) 2016-05-04 2019-03-13 Icahn School Med Mount Sinai Trithérapie pour le traitement d'une maladie intestinale inflammatoire
WO2017214376A1 (fr) * 2016-06-10 2017-12-14 Elwha Llc Compositions et procédés comprenant une lignée cellulaire de lymphocytes b exprimant une immunoglobuline membranaire différente d'une immunoglobuline sécrétée et fonction cytolytique
MA45245A (fr) 2016-06-12 2019-04-17 Millennium Pharm Inc Méthode de traitement de maladie intestinale inflammatoire
WO2018104893A1 (fr) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Anticorps anti-alpha4-beta7 présentant une liaison à fcrn et/ou une demi-vie augmentées
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US20200179486A1 (en) 2017-04-28 2020-06-11 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
WO2019014572A1 (fr) 2017-07-14 2019-01-17 Pfizer, Inc. Anticorps dirigés contre madcam
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
KR20210027427A (ko) 2018-07-03 2021-03-10 브리스톨-마이어스 스큅 컴퍼니 재조합 단백질 생산 방법
KR20210074341A (ko) 2018-10-10 2021-06-21 베링거 인겔하임 인터내셔날 게엠베하 고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
US20220098329A1 (en) * 2018-11-30 2022-03-31 Memorial Sloan Kettering Cancer Center Heterodimeric tetravalency and specificity antibody compositions and uses thereof
CN113660953A (zh) 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
GB2597416A (en) 2019-04-12 2022-01-26 Geltor Inc Recombinant elastin and production thereof
MA55735A (fr) * 2019-04-17 2022-02-23 Millennium Pharm Inc Polythérapie à base d'inhibiteur d'alpha4bêta7 et d'inhibiteur d'il-23
MX2021015301A (es) * 2019-06-10 2022-02-03 Takeda Pharmaceuticals Co Métodos de cultivo celular y composiciones para la producción de anticuerpos.
CN114025843A (zh) * 2019-06-10 2022-02-08 武田药品工业株式会社 抗体纯化方法及其组合物
CN114514311A (zh) 2019-08-01 2022-05-17 百时美施贵宝公司 改进补料分批细胞培养物中蛋白质产量的方法
KR20230073270A (ko) 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 생산 방법
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
US20240390869A1 (en) 2021-09-21 2024-11-28 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
EP4540289A2 (fr) 2022-06-16 2025-04-23 Cephalon LLC Immunoconjugués anticorps anti-pd1-il2 atténuée et leurs utilisations
WO2024249568A1 (fr) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Compositions d'anticorps anti-intégrine alpha4beta7 et procédés d'utilisation
WO2024252368A2 (fr) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Procédés et compositions pour le traitement de la rectocolite hémorragique
US20250195677A1 (en) 2023-12-19 2025-06-19 Cephalon Llc Uses for attenuated il-2 immunoconjugates
CN117777292B (zh) * 2023-12-28 2024-10-18 天津大学 抗整合素α4β7纳米抗体及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3220049A1 (de) 1982-05-27 1983-12-01 Universal Maschinenfabrik Dr. Rudolf Schieber GmbH & Co KG, 7081 Westhausen Strick- und umhaengeschlosskombination fuer v-bett-flachstrickmaschinen mit schiebernadeln
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) * 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
ATE114478T1 (de) 1987-08-11 1994-12-15 Univ Leland Stanford Junior Verfahren zur kontrolle der leukozyten- extravasation.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5223392A (en) * 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5558864A (en) 1991-03-06 1996-09-24 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies
US5665595A (en) * 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
EP0590058B1 (fr) 1991-06-14 2003-11-26 Genentech, Inc. ANTICORP HUMANISE specifique pour heregulin
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU674302B2 (en) 1992-02-12 1996-12-19 Biogen Idec Ma Inc. Treatment for inflammatory bowel disease
WO1994012214A1 (fr) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Anticorps humanises reagissant avec la cd-18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
ES2137354T3 (es) 1993-01-12 1999-12-16 Biogen Inc Moleculas de anticuerpo anti-vla4 recombinante.
ATE161730T1 (de) 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE122006000043I1 (de) 1994-01-25 2007-02-15 Elan Pharm Inc Humanisierte Antik¦rper gegen das Leukozytenadh{sionsmolek}l vla-4
US6551593B1 (en) * 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin

Also Published As

Publication number Publication date
ATE321788T1 (de) 2006-04-15
CA2263106C (fr) 2010-08-03
US7402410B2 (en) 2008-07-22
DE69735596D1 (de) 2006-05-18
DK0918797T3 (da) 2006-07-31
EP0918797B2 (fr) 2015-09-23
IL128052A (en) 2006-08-20
PT918797E (pt) 2006-08-31
IL175570A0 (en) 2006-09-05
BR9711079A (pt) 2000-06-06
AU3972897A (en) 1998-03-06
LTC0918797I2 (lt) 2017-05-10
LU92596I2 (fr) 2015-01-12
IL128052A0 (en) 1999-11-30
CN1227607A (zh) 1999-09-01
AU730326C (en) 2005-06-16
US20060292140A1 (en) 2006-12-28
CA2263106A1 (fr) 1998-02-19
US20090011464A1 (en) 2009-01-08
BRPI9711079B8 (fr) 2021-05-25
US7147851B1 (en) 2006-12-12
WO1998006248A3 (fr) 1998-05-07
EP0918797B1 (fr) 2006-03-29
AU730326B2 (en) 2001-03-01
DK0918797T4 (en) 2016-01-11
JP2008281562A (ja) 2008-11-20
EP1710314A1 (fr) 2006-10-11
EP0918797A2 (fr) 1999-06-02
NZ334226A (en) 2000-10-27
SI0918797T2 (sl) 2016-01-29
WO1998006248A2 (fr) 1998-02-19
HK1021822A1 (en) 2000-07-07
ES2262186T5 (es) 2015-12-11
DE69735596T3 (de) 2016-02-25
DE69735596T2 (de) 2006-12-21
CN100406562C (zh) 2008-07-30
JP4171071B2 (ja) 2008-10-22
ES2262186T3 (es) 2006-11-16
JP2001507210A (ja) 2001-06-05
JP2010246548A (ja) 2010-11-04
SI0918797T1 (sl) 2006-10-31
JP5166483B2 (ja) 2013-03-21
BRPI9711079B1 (pt) 2017-06-20
JP4578536B2 (ja) 2010-11-10

Similar Documents

Publication Publication Date Title
BE2014C068I2 (fr)
PT699755E (pt) Metodo para obtencao de imunoglobulinas modificadas com imunogenicidade reduzida de dominios variaveis de anticorpos de murideo composicoes que as contem
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
WO1999037681A3 (fr) Procede servant a preparer des fragments d'anticorps
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
EP1362868A3 (fr) Anticorps monoclonaux humanisés et chimériques se liant au récepteur du facteur de croissance épidermique (EGF-R)
DE69000338D1 (de) Expressionssystem zur herstellung von chimaeren monoklonalen antikoerpern.
WO1998033919A3 (fr) Anticorps anti-alpha-v beta-3 humanises de recombinaison, acides nucleiques codant lesdits anticorps et leurs procedes d'utilisation
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
CA2068222A1 (fr) Anticorps monoclonaux
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
WO1998012334A3 (fr) Anticorps chimeres humanises a chaine unique contre l'alpha-2-antiplasmine
RU94045907A (ru) Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты